Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Finished Goods (2016 - 2018)

Historic Finished Goods for Theravance Biopharma (TBPH) over the last 6 years, with Q3 2018 value amounting to $3.5 million.

  • Theravance Biopharma's Finished Goods fell 2292.49% to $3.5 million in Q3 2018 from the same period last year, while for Sep 2018 it was $3.5 million, marking a year-over-year decrease of 2292.49%. This contributed to the annual value of $5.0 million for FY2017, which is 4279.64% up from last year.
  • Latest data reveals that Theravance Biopharma reported Finished Goods of $3.5 million as of Q3 2018, which was down 2292.49% from $4.0 million recorded in Q2 2018.
  • In the past 5 years, Theravance Biopharma's Finished Goods ranged from a high of $7.5 million in Q3 2014 and a low of $2.0 million during Q2 2017
  • In the last 5 years, Theravance Biopharma's Finished Goods had a median value of $4.6 million in 2017 and averaged $4.3 million.
  • In the last 5 years, Theravance Biopharma's Finished Goods crashed by 5875.17% in 2016 and then skyrocketed by 9959.86% in 2018.
  • Over the past 5 years, Theravance Biopharma's Finished Goods (Quarter) stood at $5.6 million in 2014, then crashed by 43.71% to $3.1 million in 2015, then rose by 12.44% to $3.5 million in 2016, then surged by 42.8% to $5.0 million in 2017, then tumbled by 30.29% to $3.5 million in 2018.
  • Its Finished Goods stands at $3.5 million for Q3 2018, versus $4.0 million for Q2 2018 and $4.6 million for Q1 2018.